within Pharmacolibrary.Drugs.ATC.C;

model C08CA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 48 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.014166666666666666,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Felodipine is a dihydropyridine calcium channel blocker used primarily for the treatment of hypertension and angina pectoris. It works by relaxing vascular smooth muscle and reducing peripheral resistance. Felodipine is an approved and widely used antihypertensive agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Dunselman, PH, &amp; Edgar, B (1991). Felodipine clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> 21(6) 418–430. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199121060-00003&quot;>10.2165/00003088-199121060-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1782737/&quot;>https://pubmed.ncbi.nlm.nih.gov/1782737</a></p></li><li><p>Dunselman, PH, et al., &amp; Wesseling, H (1989). Oral pharmacokinetics of felodipine in patients with congestive heart failure: variable prediction using intravenous data. <i>Journal of clinical pharmacology</i> 29(6) 518–523. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1989.tb03374.x&quot;>10.1002/j.1552-4604.1989.tb03374.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2754021/&quot;>https://pubmed.ncbi.nlm.nih.gov/2754021</a></p></li><li><p>Eriksson, UG, et al., &amp; Regårdh, CG (1991). Pharmacokinetics of the enantiomers of felodipine in the dog after oral and intravenous administration of a pseudoracemic mixture. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 21(1) 75–84. DOI:<a href=&quot;https://doi.org/10.3109/00498259109039452&quot;>10.3109/00498259109039452</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2003369/&quot;>https://pubmed.ncbi.nlm.nih.gov/2003369</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C08CA02;
